Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc., a prominent player in the life sciences sector, is revolutionizing the field of proteomics. The company is known for its development and commercialization of the Proteograph Product Suite, an integrated solution designed to unlock deep, unbiased biological information. The suite comprises consumables, automation instrumentation, and software that enable comprehensive proteomic profiling and sample analysis, providing researchers with a detailed view of the proteome.
Seer's technology is built around proprietary engineered nanoparticles, which offer unmatched depth and scale in proteomic studies. This innovative approach allows for the detection of over 6,000 proteins and more than 55,000 peptide IDs in complex samples, such as plasma. The Proteograph Product Suite is designed for ease of use, with features like minimal hands-on time and fully automated workflows, making it accessible to a wide range of research labs.
The company primarily targets academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies, offering its products for non-diagnostic and non-clinical purposes. Seer has established significant collaborations with industry leaders like Discovery Life Sciences, Bruker Scientific LLC, and Thermo Electron North America LLC, enhancing its market reach and technological capabilities.
Recently, Seer has made headlines through its partnership with Panome Bio to integrate deep, unbiased proteomics with metabolomics, aiming to accelerate research in biomarker discovery and drug development. The collaboration is expected to facilitate groundbreaking studies with robust pathway analyses, significantly advancing the understanding of biology and disease.
In another noteworthy development, Seer announced a major study published in Nature Communications, conducted in collaboration with Weill Cornell Medicine. This research showcased Seer's Proteograph workflow's potential to unveil novel proteogenomic insights, linking genetic variation with protein abundance at peptide level resolution. This study is a testament to Seer's commitment to advancing multi-omics research and enhancing precision medicine.
Seer's financial outlook remains optimistic despite macroeconomic challenges. The company continues to drive the adoption of its Proteograph Product Suite by expanding its Technology Access Center and increasing its commercial reach. As more customer data and third-party publications highlight the power of Seer's technology, the company anticipates growing adoption and impact in the scientific community.
In summary, Seer, Inc. is at the forefront of proteomics, offering transformative solutions that provide unparalleled insights into the proteome, thus paving the way for significant advancements in biological research and precision medicine.
Seer, Inc. (Nasdaq: SEER) reported Q3 2022 revenue of $4.0 million, up from $2.2 million in Q3 2021, mainly due to increased sales of the Proteograph Product Suite. The gross profit was $1.9 million with a gross margin of 49%. Operating expenses rose to $27.0 million, leading to a net loss of $24.0 million, compared to a loss of $18.4 million in the previous year. Seer maintains a full-year revenue guidance of $14.0 million to $16.0 million.
Seer, Inc. (NASDAQ: SEER) will report its Q3 2022 financial results on November 8, 2022, at 1:30 p.m. PT. The conference call will be available via webcast on Seer's investor website, with a replay posted afterward. Seer specializes in developing innovative proteomics solutions through its Proteograph Product Suite, designed for quick and comprehensive analysis. This offering aims to enhance laboratory efficiency and accessibility.
Seer, a life sciences company based in Redwood City, California, announced its participation in the Morgan Stanley Global Healthcare Conference in New York City on September 13, 2022. Management will partake in a fireside chat at 8:35 a.m. Eastern Time. The session will be available via a live webcast on the company's investor website, with an archived replay to follow. Seer specializes in proteomics, offering the Proteograph Product Suite for deep proteomic analysis, designed for research use only.
Seer, Inc. announced the publication of a study demonstrating advancements in its Proteograph Product Suite for comprehensive proteomic analysis. The study, published in Advanced Materials, highlights the integration of proteomics methods, nanoengineering, and machine learning to capture thousands of proteins and discover novel biomarkers. CEO Omid Farokhzad emphasized the technology's capacity for deep interrogation of the proteome, enhancing research capabilities globally. The Proteograph suite combines engineered nanoparticles and software for rapid, scalable proteomics.
Seer, Inc. (Nasdaq: SEER) reported a revenue increase to $3.6 million for Q2 2022, up from $1.3 million in Q2 2021, driven by sales of the Proteograph Product Suite. The Proteograph™ Analysis Suite 2.0 was launched, enhancing their competitive edge in proteogenomics. However, the net loss for the quarter widened to $22.8 million compared to $16.6 million in the prior year. Operating expenses grew to $25.0 million, influenced by employee costs and facility expansions. The company maintains a full-year revenue guidance of $14.0 million to $16.0 million.
Seer Inc. (NASDAQ: SEER) announced the launch of its new Proteogenomics Workflow, integrating deep proteomics with genomics via the Proteograph Analysis Suite 2.0. This advancement allows for high-resolution, sample-specific analysis, enabling researchers to identify novel protein variants critical for health and disease understanding. The launch follows the formation of the Proteogenomics Consortium with Discovery Life Sciences and SCIEX to enhance biomarker discovery. The software is immediately available to customers, promoting broader access to advanced proteogenomics tools.
Seer Inc. (NASDAQ: SEER) has scheduled its second quarter 2022 financial results announcement for August 9, 2022, at 1:30 p.m. PT / 4:30 p.m. ET. The event will include a live webcast available on the investor section of its website, with an archived replay posted afterward. Seer is a life sciences company focused on innovative proteomics solutions, specifically through its Proteograph™ Product Suite, which enables efficient and scalable proteomic analysis designed for research purposes.
Seer, Inc. reported its first-quarter 2022 financial results, showing significant growth with $3.3 million in revenue, up from $62 thousand the previous year. This surge is attributed to the sales of the Proteograph Product Suite. The gross profit stood at $1.2 million with a 38% gross margin. However, operating expenses rose to $25 million, leading to a net loss of $23.6 million. Despite these losses, Seer anticipates full-year revenue between $14 million and $16 million, while expanding investments in commercial and R&D activities.
Seer, a life sciences company, will participate in the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 4:40 p.m. PT. The event will feature a fireside chat with Seer's management, and interested parties can access a live webcast on the investor section of Seer's website. Seer's Proteograph Product Suite offers innovative solutions for deep proteomic analysis, designed for efficiency and ease of use. This platform is intended for research purposes only and is not for diagnostic procedures.
Seer Inc. (NASDAQ: SEER) will report its Q1 2022 financial results on May 4, 2022, followed by a conference call at 2:00 p.m. Pacific Time. The company is known for its innovative Proteograph Product Suite, designed for advanced proteomic analysis. This technology allows for deep, unbiased research capabilities, making it accessible to laboratories worldwide. The company emphasizes its focus on research use only, with no current diagnostic applications.
FAQ
What is the current stock price of Seer (SEER)?
What is the market cap of Seer (SEER)?
What is Seer, Inc. known for?
What does the Proteograph Product Suite include?
Who are Seer's primary customers?
What recent collaborations has Seer announced?
What are the benefits of Seer's proprietary engineered nanoparticles?
What was the focus of Seer's recent study published in Nature Communications?
What is Seer's strategy to drive adoption of its technology?
Is the Proteograph Product Suite intended for diagnostic use?
Where is Seer, Inc. headquartered?
What potential does Seer see in its technology?
